MetaCap

Daxor (DXR) vs Lucid Diagnostics (LUCD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Daxor (DXR) has outperformed Lucid Diagnostics (LUCD) over the past year, losing 43.5% versus a loss of 64.7%. Over five years, DXR leads with a -32.3% price change compared with -95.6% for LUCD. Lucid Diagnostics is the larger company by market cap ($72.6 million vs $43.5 million), about 1.7 times the size.

Daxor converts more of its revenue into profit, with a net margin of -496.8% versus -1232.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DXR-43.52%LUCD-64.67%
+45%-15%-74%
Nov 21, 20251 yearNov 20, 2026
DXR-32.27%LUCD-96.04%
+37%-33%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DXR versus LUCD key metrics
MetricDXRLUCD
Share price$7.45$0.3727
Market cap$43.49M$72.57M
1-day change-7.33%-3.52%
YTD return-49.49%-65.81%
1-year return-43.52%-64.67%
5-year return-32.27%-95.58%
P/E ratio (TTM)6.77—
EPS (TTM)$1.10$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.45M$4.71M
Revenue growth (YoY)-8.42%+8.28%
Net income (latest FY)$-7.19M$-58.01M
Gross margin54.89%-41.73%
Operating margin-400.07%-1054.82%
Net margin-496.81%-1232.68%
52-week high$14.76$1.63
52-week low$6.94$0.303
Distance from 52-week high-49.53%-77.12%
Analyst consensusnonestrong_buy
Avg. price target upside+168.46%+973.25%
Average volume22.43K5.15M
Shares outstanding5.84M194.71M
Employees—82
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DXR has outperformed LUCD by 21.2 percentage points over the past year.
  • Daxor is more profitable, keeping -496.8 cents of every revenue dollar as net income versus -1232.7 cents for Lucid Diagnostics.
  • Lucid Diagnostics grew revenue faster in its latest fiscal year (+8.28% vs -8.42%).

About Daxor

DXR stock →

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.

Health Care · Medical/Dental Instruments

About Lucid Diagnostics

LUCD stock →

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.

Health Care · Medical/Dental Instruments · 82 employees

DXR vs LUCD FAQ

Which is bigger, Daxor or Lucid Diagnostics?

Lucid Diagnostics (LUCD) is larger, with a market capitalization of $72.57M compared with $43.49M for Daxor (DXR).

Which stock has performed better over the past year, DXR or LUCD?

DXR returned -43.52% over the past 12 months, compared with -64.67% for LUCD (price return, excluding dividends). Past performance does not predict future results.

Are Daxor and Lucid Diagnostics in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons